Lysosome targeted therapies in hematological malignancies.

Lysosomes are dynamic organelles integral to cellular homeostasis, secretory pathways, immune responses, and cell death regulation. In cancers, lysosomes become dysregulated to sustain proliferative signaling, metabolism, and invasion. In hematological malignancies such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL), leukemia cells demonstrate lysosome dysregulation with increased lysosomal activity, mTORC1 signaling, catabolic reactions, and autophagy.

Assessment practices for dietetic students: An updated systematic review (2017-2024).

Aim: Evaluate assessment practices and outcomes for dietetic students and compare findings with those from a previous systematic review.

Methods: A systematic review was conducted whereby four databases (MEDLINE, Embase, Cumulative Index in Nursing and Allied Health Literature, and Education Resources Information Centre) were searched on 11 October 2023 with terms related to dietetics, students, and assessment. The search was repeated on 8 January 2025 to identify new publications.

Immune Response of Nile Tilapia (Oreochromis niloticus) Vaccinated With Diatom-Based Oral Vaccines Against Piscine Francisellosis.

Piscine francisellosis is a highly infectious and economically significant disease caused by Francisella orientalis in tilapia (Oreochromis spp.). There are currently no approved treatments or commercial vaccines for this disease in cultured fish.

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36 TeV with the ATLAS Detector at the LHC.

This Letter presents a search for highly ionizing magnetic monopoles in 262  μb^{-1} of ultraperipheral Pb+Pb collision data at sqrt[s_{NN}]=5.36  TeV collected by the ATLAS detector at the LHC. A new methodology that exploits the properties of clusters of hits reconstructed in the innermost silicon detector layers is introduced to study highly ionizing particles in heavy-ion data.

Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease.

In early 2020, severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infections leading to COVID-19 disease reached a global level leading to the World Health Organization (WHO) declaration of a pandemic. Scientists around the globe rapidly responded to try and discover novel therapeutics and repurpose extant drugs to treat the disease. This work describes the preclinical discovery efforts that led to the invention of PF-07321332 (nirmatrelvir, ), a potent and orally active inhibitor of the SARS CoV-2 main protease (M) enzyme.